GlassScriptPhysician profile
Sandra L Buchanan
NPI 1003923731
$3,549.77
in general payments reported to CMS, 2019-2025
28 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $403 · 2021: $487 · 2022: $474 · 2023: $623 · 2024: $635 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,610.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $550.42 | 2019-2025 | Ubrelvy, Vraylar |
| Novartis Pharmaceuticals Corporation | $359.50 | 2019-2025 | |
| Pfizer INC. | $337.77 | 2019-2024 | |
| Amgen INC. | $295.01 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $226.13 | 2019-2025 | Shingrix, Arexvy |
| Novo Nordisk INC | $202.37 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Sumitomo Pharma America, INC. | $191.42 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $168.95 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astrazeneca Pharmaceuticals LP | $158.21 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Allergan, INC. | $148.04 | 2019-2020 | |
| Daiichi Sankyo INC. | $113.51 | 2020-2024 | Injectafer |
| Exact Sciences Corporation | $100.95 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.98 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $86.85 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $76.27 | 2021-2025 | Freestyle Libre 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.41 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $53.36 | 2021-2023 | Xarelto |
| Astellas Pharma US INC | $46.04 | 2023-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $46.01 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $42.37 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $35.87 | 2019 | |
| Amarin Pharma, INC. | $34.54 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $30.99 | 2020-2021 | |
| Mylan Specialty L.P. | $23.58 | 2024 | Yupelri |
| Averitas Pharma INC. | $21.14 | 2024 | Qutenza |
| Azurity Pharmaceuticals, INC. | $17.13 | 2025 | |
| Eisai INC. | $16.71 | 2021 | |
| Sanofi Pasteur INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.